What are all the things that aspirin does? This fascinating but simple and cheap drug has an assured future

British Medical Journal

Volumn 327, Issue 7415, 2003, Pages 572-573

  Flower, Rod ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTIPYRETIC ANALGESIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; APOPTOSIS; BLEEDING; BREAST CANCER; CANCER; CANCER PREVENTION; CANCER RISK; CELL PROTECTION; COLORECTAL CANCER; CORRELATION ANALYSIS; DIET; DRUG COST; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CANCER; FEVER; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; LONG TERM CARE; LONG TERM EXPOSURE; LOW DRUG DOSE; NONHUMAN; OVARY CANCER; PAIN; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH PROTECTION; STROKE; THROMBOCYTE AGGREGATION; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 0141797518     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
2. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6.
3. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7.
4. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev 2002;11:535-42.
5. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
6. Thun MJ, Henley SJ, Patrono C, Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
7. Paterson JR, Lawrence JR. Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. QJM 2001;94:445-8.
8. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
9. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000;57:1586-91.
10. Gao F, Bales KR, Dodel RC, Liu J, Chen X, Hample H, et al. NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line. Brain Res Mol Brain Res 2002;105:108-14.
11. Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann N Y Acad Sci 2002;962:360-71.
12. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-31.